Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Total Non-Current Liabilities (2023 - 2024)

Historic Total Non-Current Liabilities for Artiva Biotherapeutics (ARTV) over the last 2 years, with Q4 2024 value amounting to $22.9 million.

  • Artiva Biotherapeutics' Total Non-Current Liabilities fell 1073.16% to $22.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $22.9 million, marking a year-over-year decrease of 1073.16%. This contributed to the annual value of $22.9 million for FY2024, which is 1073.16% down from last year.
  • As of Q4 2024, Artiva Biotherapeutics' Total Non-Current Liabilities stood at $22.9 million, which was down 1073.16% from $24.5 million recorded in Q3 2024.
  • Artiva Biotherapeutics' Total Non-Current Liabilities' 5-year high stood at $25.6 million during Q4 2023, with a 5-year trough of $22.9 million in Q4 2024.